Cabot Corp (CBT)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$81.48+0.36%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
Research Workspace
Put CBT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Cash flow from operations near $77M per quarter: not reported for Q3 FY2026 vs 77 USD_MILLIONS target.
View ThesisRevenue is contracting — down about 5% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 9%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCBT's growth in the Battery Materials segment has to keep compounding to justify the price. Revenue grew 9.5% year over year, and the last quarter beat expectations. It trades at 12.5× P/E versus a peer median of 18×. The price reflects less growth than forecast, indicating modest expectations. A specific risk is the potential credibility hit if CBT cuts guidance after recently raising it. Peer multiples imply a price about 10% above where it trades. This read is provisional; the thesis is on watch due to cash flow from operations near the target not being reported.
Trailing returns as of 2026-09-04. CBT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering CBT (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for CBT in the last 4 months.
Continue this research
Compare CBT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CBT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put CBT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Leadership transition with new CEO Erica McLaughlin
CEO stock sale raises concerns about leadership stability.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $81.48
The last 12 months of price, then the range of analyst 12-month targets from today’s $81.48.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Leadership transition with new CEO Erica McLaughlin
CEO stock sale raises concerns about leadership stability.
Advances: Drive growth in Battery Materials segment
Battery Materials segment growth supports management's growth objective.
Downgrade suggests potential challenges to growth expectations.
Advances: Leadership transition with new CEO Erica McLaughlin
New CEO may enhance leadership and strategic direction.
CEO transition may disrupt operational stability.
Advances: Maintain strong cash flow from operations
Growing demand supports strong cash flow from operations.
Advances: Optimize capital structure with new credit agreement
New supply agreement enhances capital structure optimization.
